Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Bessone

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Journal of Hepatology|July 20, 2014
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis CJean-Pierre Bronowicki, Vlad Ratziu, Adrian Gadano, et al.
Annals of Hepatology|September 6, 2012
Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjectsMaría Virginia Reggiardo, Fabián Fay, Mario Tanno, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2015
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia-Horng Kao, Donald M Jensen, Michael P Manns, et al.
Gastroenterology|April 8, 2014
Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injuryMercedes Robles-Diaz, M Isabel Lucena, Neil Kaplowitz, et al.
Oncotarget|May 19, 2025
Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinomaLeonardo Gomes da Fonseca, Federico Piñero, Margarita Anders, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 25, 2015
Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 casesFernando Bessone, M I Lucena, Marcelo G Roma, et al.
Archives of Toxicology|December 5, 2023
Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registriesInmaculada Medina-Cáliz, Judith Sanabria-Cabrera, Marina Villanueva-Paz, et al.
Pharmacological Research|December 10, 2023
Prior drug allergies are associated with worse outcome in patients with idiosyncratic drug-induced liver injury: A machine learning approach for risk stratificationHao Niu, Pablo Solis-Muñoz, Miren García-Cortés, et al.
Annals of Hepatology|May 5, 2019
Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH)Juan P Arab, Juan P Roblero, Jose Altamirano, et al.
Journal of Medical Virology|January 20, 2018
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world studySebastián Marciano, Leila Haddad, María V Reggiardo, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Journal of Hepatology|July 20, 2014
Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis CJean-Pierre Bronowicki, Vlad Ratziu, Adrian Gadano, et al.
Annals of Hepatology|September 6, 2012
Natural history of hepatitis C virus infection in a cohort of asymptomatic post-transfused subjectsMaría Virginia Reggiardo, Fabián Fay, Mario Tanno, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2015
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia-Horng Kao, Donald M Jensen, Michael P Manns, et al.
Gastroenterology|April 8, 2014
Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injuryMercedes Robles-Diaz, M Isabel Lucena, Neil Kaplowitz, et al.
Oncotarget|May 19, 2025
Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinomaLeonardo Gomes da Fonseca, Federico Piñero, Margarita Anders, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 25, 2015
Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 casesFernando Bessone, M I Lucena, Marcelo G Roma, et al.
Archives of Toxicology|December 5, 2023
Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registriesInmaculada Medina-Cáliz, Judith Sanabria-Cabrera, Marina Villanueva-Paz, et al.
Pharmacological Research|December 10, 2023
Prior drug allergies are associated with worse outcome in patients with idiosyncratic drug-induced liver injury: A machine learning approach for risk stratificationHao Niu, Pablo Solis-Muñoz, Miren García-Cortés, et al.
Annals of Hepatology|May 5, 2019
Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH)Juan P Arab, Juan P Roblero, Jose Altamirano, et al.
Journal of Medical Virology|January 20, 2018
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world studySebastián Marciano, Leila Haddad, María V Reggiardo, et al.
Pageof 8